Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Day One Biopharmaceuticals (DAWN) Income from Non-Controlling Interests (2023 - 2025)

Historic Income from Non-Controlling Interests for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Q3 2025 value amounting to $19.7 million.

  • Day One Biopharmaceuticals' Income from Non-Controlling Interests rose 15455.95% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $145.3 million, marking a year-over-year increase of 7373.69%. This contributed to the annual value of $88.4 million for FY2024, which is 5323.24% down from last year.
  • Day One Biopharmaceuticals' Income from Non-Controlling Interests amounted to $19.7 million in Q3 2025, which was up 15455.95% from $30.3 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Income from Non-Controlling Interests ranged from a high of $62.4 million in Q1 2024 and a low of -$36.2 million during Q3 2024
  • Its 3-year average for Income from Non-Controlling Interests is $32.1 million, with a median of $40.9 million in 2023.
  • Per our database at Business Quant, Day One Biopharmaceuticals' Income from Non-Controlling Interests plummeted by 17834.24% in 2024 and then surged by 96206.65% in 2025.
  • Quarter analysis of 3 years shows Day One Biopharmaceuticals' Income from Non-Controlling Interests stood at $54.5 million in 2023, then increased by 8.68% to $59.2 million in 2024, then tumbled by 66.7% to $19.7 million in 2025.
  • Its last three reported values are $19.7 million in Q3 2025, $30.3 million for Q2 2025, and $36.0 million during Q1 2025.